Pharmascience

Type: Company
Name: Pharmascience
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Oxford Pharmascience options exercised

StockMarketWire.com - Oxford Pharmascience Group has issued 8,125,000 ordinary shares following the exercise of options under the company's approved share option plan by former director Nigel Theobald. At 2:54pm: [LON:OXP] Oxford Pharmascience Group PLC ... [Published Stock Market Wire - Apr 14 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

GILEAD SCIENCES : Pendopharm Announces Priority Review of New Therapy to Support Treatment of Patients with Hepatitis C

By a News Reporter-Staff News Editor at China Weekly News -- New hepatitis C (HCV) treatment regimens have advanced rapidly in recent years, including the recent Health Canada approval of interferon-free therapy. To support patients to access these newest ... [Published 4 Traders - Apr 10 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Derby export firms share secrets to their success

The PM has demanded UK exports rise to £1 trillion by 2020. To mark UK Trade and Investment's Export Week, we talk to Derby businesses that are helping to hit UK Plc's overseas sales target.WHILE English football clubs have struggled in Europe this season, ... [Published Derby Telegraph - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

Proactive Invs UK Ld : Innovation Forum

Innovation Forum, Thursday April 10.Proactive Investors, the international financial news provider to one of the world's largest communities of sophisticated investors, is pleased to unveil the line-up for the London Innovation Forum on Thursday (April ... [Published Investegate - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Oxford Pharmascience : CEO Showcasing Ibuprofen Taste Masked Products

Oxford Pharmascience Group plc("Oxford Pharmascience" or the "Company")CEO Showcasing Ibuprofen Taste Masked ProductsOxford Pharmascience, theA copy of the presentation given will be made available on the Company's website after the event. Oxford Pha ... [Published Investegate - Apr 08 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

ValiRx, e-Therapeutics, Oxford Pharmascience and Action Hotels to present next week

Next week's Proactive forum promises to be a dynamic evening as it showcases some of the most exciting non-resource companies, which are hot on the market right now. Joining us on Thursday, April 10 at the Chesterfield Mayfair Hotel will be ValiRx ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 3 reports

Pendopharm Announces Priority Review of New Therapy to Support Treatment of Patients with Hepatitis C

MONTREAL--(BUSINESS WIRE)--New hepatitis C (HCV) treatment regimens have advanced rapidly in recent years, including the recent Health Canada approval of interferon-free therapy. To support patients to access these newest options, Pendopharm, a division ... [Published Business Wire Health News - Mar 31 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Oxford Pharmascience : Director/PDMR Shareholding

Oxford Pharmascience Group plc("Oxford Pharmascience" or the "Company")Director/PDMR ShareholdingOxford Pharmascience today announces that it was notified on 25 March 2014, that Mr. David Norwood, Non-executive Chairman of the Company, bought 1,000,000 ... [Published Investegate - Mar 26 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Oxford Pharmascience initiates dosing in gastric irritation study

Oxford Pharmascience Group Plc, a specialty pharmaceutical company, has initiated dosing of subjects in its pilot clinical study of OXP001 400mg Ibuprofen. OXP001 delivers 400mg of ibuprofen via the company's OXPzero technology in a novel salt oral formulation ... [Published Individual.com - Mar 18 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 1 reports

Proactive news summary, featuring Fastnet, Weatherly, ZincOx, Brady, Angle, Oxford Pharmascience, Blur, Telit

The top 50 dividend-paying companies on AIM returned more than 37% over the last 12 months, according to a report by Allenby Capital. The City firm recorded the progress of the highest yielding 50 companies on the junior market. The average return (including ... [Published Proactiveinvestors United Kingdom RSS feed - Mar 17 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 3 reports

Oxford Pharmascience appoints R&D director

Source: SMW Oxford Pharmascience, the speciality pharmaceutical company that redevelops medicines to make them better, safer and easier to take, has appointed Dr Liz King as director of research & development to manage all of the company's development ... [Published Telegraph - Mar 17 2014]
First reported Mar 10 2014 - Updated Mar 10 2014 - 3 reports

Oxford Pharmascience starts dosing in ibuprofen study

() has started dosing patients in the pilot clinical study of a variation of ibuprofen that is targeting the side effects of the anti-inflammatory drug.The group specialises is reformulating drugs to make them both easier to take and more effective.The ... [Published Proactive Investors.co.uk - Mar 10 2014]

Quotes

...in Canada ," said Jordan Feld , MD, MPH, Staff Hepatologist, Toronto Western Hospital , Department of Medicine , Division of Gastroenterology . "Interferon has been the main stumbling block to treatment in the past. New regimens without interferon are a huge advance, giving us higher cure rates and shortened treatment duration with a lot fewer side effects. This gives us our best opportunity to successfully treat and cure Canadians with hepatitis C" added Dr. Feld. Company Information Pendopharm is a division of Pharmascience Inc. , a Canadian privately-owned company...
"The market was a great source of revenue for us as a startup company and gave us the initial chance to raise a lot of money while we put the effort into further developing our research and development arm."

More Content

All (59) | News (56) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Oxford Pharmascience options exercised [Published Stock Market Wire - Apr 14 2014]
Venlafaxine section 8 decision follows “roadmap... [Published Lexology - Apr 14 2014]
GILEAD SCIENCES : Pendopharm Announces Priority... [Published 4 Traders - Apr 10 2014]
Derby export firms share secrets to their success [Published Derby Telegraph - Apr 09 2014]
Proactive Invs UK Ld : Innovation Forum [Published Investegate - Apr 08 2014]
Innovation Forum [Published TrustNet - Apr 08 2014]
Oxford Pharmascience : CEO Showcasing Ibuprofen... [Published Investegate - Apr 08 2014]
ValiRx, e-Therapeutics, Oxford Pharmascience an... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]
ValiRx, e-Therapeutics, Oxford Pharmascience an... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]
ValiRx, e-Therapeutics, Oxford Pharmascience an... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]
ValiRx, e-Therapeutics, Oxford Pharmascience an... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]
Gilead Sciences : Pendopharm Secures Priority R... [Published 4 Traders - Apr 03 2014]
Pendopharm Announces Priority Review of New The... [Published Business Wire Health News - Mar 31 2014]
Pendopharm announces Priority Review of new the... [Published Digital Journal - Mar 31 2014]
Pendopharm announces Priority Review of new the... [Published BusinessWeek - Mar 31 2014]
In the papers: 'Just Eat to be valued at £1.47 ... [Published Proactiveinvestors United Kingdom RSS feed - Mar 27 2014]
Carnival Chairman reduces stake by around a qua... [Published BullBearings - Mar 26 2014]
Oxford Pharmascience : Director/PDMR Shareholding [Published Investegate - Mar 26 2014]
Oxford Pharmascience initiates dosing in gastri... [Published Individual.com - Mar 18 2014]
Proactive news summary, featuring Fastnet, Weat... [Published Proactiveinvestors United Kingdom RSS feed - Mar 17 2014]
Oxford Pharmascience appoints R&D director [Published Telegraph - Mar 17 2014]
Oxford Pharmascience adds R&D director to team [Published Proactiveinvestors United Kingdom RSS feed - Mar 17 2014]
Oxford Pharmascience : Appointment of Director ... [Published Investegate - Mar 17 2014]
Oxford Pharmascience : Grant of Share Options [Published Investegate - Mar 12 2014]
Proactive news summary, featuring Fyffes, Oxfor... [Published Proactive Investors.co.uk - Mar 10 2014]
Oxford Pharmascience: Appointment of Non-Execut... [Published FirstWord Pharma - Mar 10 2014]
Oxford Pharmascience starts dosing in ibuprofen... [Published Proactive Investors.co.uk - Mar 10 2014]
Oxford Pharma begins OXP001 pilot study [Published Telegraph - Mar 10 2014]
Initiation of Pilot Clinical Study [Published TrustNet - Mar 10 2014]
Oxford Pharmascience adds to board [Published PMLive - Mar 10 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Pendopharm Announces Priority Review of New The... [Published Business Wire Health News - Mar 31 2014]
MONTREAL--(BUSINESS WIRE)--New hepatitis C (HCV) treatment regimens have advanced rapidly in recent years, including the recent Health Canada approval of interferon-free therapy. To support patients to access these newest options, Pendopharm, a division ...
How a U.S. tax loophole gave Paladin Labs’ foun... [Published Financial Post | Business » Entrepreneur - Mar 09 2014]
MONTREAL •There are three things you should know about Jonathan Goodman. He’s a “control freak” (his words) who’s made big money for investors. He was in a coma and nearly died. He believes the tax system loophole that allowed him to sell specialty ...
4d pharma to float [Published BvDEP Zephyr Editorial News - Feb 05 2014]
4d pharma, a UK pharmaceutical company chaired by the founding shareholder of Oxford Pharmascience David Norwood, has got the ball rolling for an initial public offering (IPO) on London’s Alternative Investment Market by mid-February.... ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.